Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...
There is no need to waste important AAV samples. Bio-Techne’s automated, high-throughput systems allow the characterization of AAVs in sample volumes as low as 3 µL while maintaining high levels of ...
Gene therapy (introducing genetic material into living cells to fix, replace, enhance, or block a faulty gene) is rapidly gaining traction as a strategy for the treatment of genetic diseases. The ...
As gene therapies advance toward indications with larger patient populations, adeno-associated virus (AAV) manufacturers are under growing pressure to deliver high-quality vectors at substantially ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
Quantification of empty and full adeno-associated virus (AAV) capsids is crucial for maximizing viral vectors used in gene therapy. The launch of the Vericheck ddPCR Empty-Full Capsid Kit expands this ...
Delivers 2x increase in AAV titers compared to market alternates. Reduce plasmid input, halve the bioreactors, and significantly lower cost per dose. HORSHAM, Pa., Aug. 12, 2025 /PRNewswire/ -- In a ...
Viral vectors are key delivery tools for advanced therapies, enabling gene transfer to treat inherited disorders, cancer and other serious diseases. Despite rapid clinical progress, manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results